08:41 EDT Agios up 13% at $33.50 after announcing pursuit of approval for mitapivat
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharmaceuticals to pursue U.S. accelerated approval for mitapivat
- Citi ups Agios target, opens ‘upside 90-day catalyst watch’
- Agios Pharmaceuticals Pyrukynd approved for adults in UAE
- Agios Pharmaceuticals Signals Confident Path After AQVESME Win
- Regulatory Delays Threaten Agios Pharmaceuticals’ Drug Pipeline, Costs and Revenue Outlook